Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引：0
|
作者：
Robert Deicher
Walter H. Hörl
机构：
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源：
Drugs | 2004年 / 64卷
关键词：
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码：499 / 509
页数：10
相关论文
共 50 条
  • [31] OPTIMAL TARGET HEMOGLOBIN LEVEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ANEMIA TREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS: CONTROVERSIAL ISSUES
    Kozlovskaya, L. V.
    Milovanov, Yu. S.
    Milovanova, L. Yu
    ARCHIV EUROMEDICA, 2011, 3 : 55 - 64
  • [32] Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: A literature review
    Ranchon, Florence
    Hedoux, Stephanie
    Laville, Maurice
    Fouque, Denis
    Decullier, Evelyne
    Chapuis, Francois
    Huot, Laure
    NEPHROLOGIE & THERAPEUTIQUE, 2010, 6 (02): : 97 - 104
  • [33] Comparison of rates and risk factors for development of anaemia and erythropoiesis-stimulating agent utilization after radical or partial nephrectomy
    Woldrich, Jeffrey
    Mehrazin, Reza
    Bazzi, Wassim M.
    Bagrodia, Aditya
    Kopp, Ryan P.
    Malcolm, John B.
    Kane, Christopher J.
    Patterson, Anthony L.
    Wan, Jim Y.
    Derweesh, Ithaar H.
    BJU INTERNATIONAL, 2012, 109 (07) : 1019 - 1025
  • [34] Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009
    Regidor, Deborah
    McClellan, William M.
    Kewalramani, Reshma
    Sharma, Amit
    Bradbury, Brian D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (05) : 1583 - 1591
  • [35] Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents
    Silver, M. R.
    Geronemus, R.
    Krause, M.
    Chen, C. Y.
    Kewalramani, R.
    Stehman-Breen, C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 123 - 131
  • [36] Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis
    Molina, Manuel
    Jose Navarro, Maria
    de Gracia, Carmen
    Alvarez, Gracia
    de Alarcon, Rosa
    Angeles Garcia, Maria
    RENAL FAILURE, 2008, 30 (08) : 778 - 783
  • [37] The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial
    Zhang, Lei
    Coombes, Jeff
    Pascoe, Elaine M.
    Badve, Sunil V.
    Dalziel, Kim
    Cass, Alan
    Clarke, Philip
    Ferrari, Paolo
    McDonald, Stephen P.
    Morrish, Alicia T.
    Pedagogos, Eugenie
    Perkovic, Vlado
    Reidlinger, Donna
    Scaria, Anish
    Walker, Rowan
    Vergara, Liza A.
    Hawley, Carmel M.
    Johnson, David W.
    REDOX REPORT, 2016, 21 (01) : 14 - 23
  • [38] High Target Hemoglobin With Erythropoiesis-Stimulating Agents Has Advantages in the Renal Function of Non-Dialysis Chronic Kidney Disease Patients
    Tsubakihara, Yoshiharu
    Gejyo, Fumitake
    Nishi, Shinichi
    Iino, Yasuhiko
    Watanabe, Yuzou
    Suzuki, Masashi
    Saito, Akira
    Akiba, Takashi
    Hirakata, Hideki
    Akizawa, Tadao
    THERAPEUTIC APHERESIS AND DIALYSIS, 2012, 16 (06) : 529 - 540
  • [39] Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights
    Macdougall, Iain C.
    Roger, Simon D.
    de Francisco, Angel
    Goldsmith, David J. A.
    Schellekens, Huub
    Ebbers, Hans
    Jelkmann, Wolfgang
    London, Gerard
    Casadevall, Nicole
    Hoerl, Walter H.
    Kemeny, David M.
    Pollock, Carol
    KIDNEY INTERNATIONAL, 2012, 81 (08) : 727 - 732
  • [40] A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan
    Mishina, Sari
    Waratani, Miina
    Onozawa, Satoshi
    Okumura, Hiroyuki
    Ito, Yuichiro
    Yasuda, Yoshinari
    NEPHROLOGY, 2023, : 446 - 455
12345